Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation.
Dalal
Bakul I
BI
Division of Hematopathology, Vancouver General Hospital, Vancouver, British Columbia, Canada. bakul.dalal@vch.ca
Horsman
Douglas E
DE
Bruyèrè
Hélène
H
Forrest
Donna L
DL
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D015321:Gene Rearrangement / Q000187:drug effects*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D034721:Mastocytosis, Systemic / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000235:genetics*; D012074:Remission Induction; D047368:Tumor Burden / Q000187:drug effects
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D020797:Receptor, Platelet-Derived Growth Factor beta